Search Results
Your search for ASCO matches 22016 pages
Showing 1 - 50Perioperative Enfortumab Vedotin Plus Pembrolizumab May Reduce Risk of Recurrence in Patients With Muscle-Invasive Bladder Cancer
The results from the randomized phase III KEYNOTE-B15/EV-304 study show that neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab significantly improved event-free survival, overall survival, and pathologic complete response rate in patients with muscle-invasive bladder cancer who were...
Medical Societies and More Respond to HHS RFI on AI Use in Clinical Care
In time for the assigned deadline of February 23, 2026, medical societies, companies, health-care systems, and more have responded to a request for information from the Department of Health and Human Services (HHS) regarding the use of artificial intelligence (AI) in clinical practice. The Request...
Advanced Nonsquamous NSCLC: FDA Grants Accelerated Approval to Zongertinib
On February 26, the U.S. Food and Drug Administration (FDA) granted accelerated approval to zongertinib (Hernexeos), a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic nonsquamous non–small cell lung cancer (NSCLC) whose tumors have HER2 tyrosine kinase domain ...
Amar Kishan, MD, on Recurrent Prostate Cancer: Hormone Therapy and Postoperative Radiotherapy
Amar Kishan, MD, University of California, Los Angeles, discusses results from an individual patient data meta-analysis of randomized trials to quantify the benefit of adding hormone therapy to postoperative radiotherapy in patients with localized prostate cancer after radical prostatectomy...
Enrique Gallardo, MD, on mCRPC: Enzalutamide With or Without Radium-223
Enrique Gallardo, MD, of Parc Taulí University Hospital, presents final overall survival results from the EORTC 1333/PEACE-3 trial, which is a phase III trial evaluating the addition of radium-223 to enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone...
Anna Clare Wilkins, PhD, MRCP, MBBChir, on Localized Prostate Cancer: MMAI-Derived Biomarker
Anna Clare Wilkins, PhD, MRCP, MBBChir, of The Institute of Cancer Research, discusses the external validation of a digital pathology-based multimodal artificial intelligence (MMAI)-derived prognostic biomarker using data from the phase III CHHiP trial. CHHiP evaluated conventional vs...
Scott Tyldesley, MD, FRCPC, on Localized Prostate Cancer: External Beam vs Brachytherapy Boost RT
Scott Tyldesley, MD, FRCPC, of BC Cancer Vancouver, reports on the 15-year survival analysis from the ASCENDE-RT trial, which randomly assigned patients to receive either prostate brachytherapy or the external-beam radiotherapy boost; both arms also received androgen-deprivation therapy....
‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?
Prostate specific antigen (PSA) screening remains one of the most controversial of “standard” medical practices. As recently as the 2026 Super Bowl, one of the more unusual TV advertisements, sponsored by a pharmaceutical company with an interest in prostate cancer treatments, extolled the virtues ...
SABCS 2025: Top Picks From a Breast Cancer Specialist
Among the high-quality abstract presentations at the annual San Antonio Breast Cancer Symposium (SABCS), a few always stand out as particularly meritorious. Each year, The ASCO Post asks its Senior Deputy Editor, breast cancer specialist Jame Abraham, MD, FACP, to offer his top picks for most...
How the Outlook on Fertility Preservation for Patients With Cancer Is Improving
Each year in the United States, about 90,000 adolescents and young adults (AYAs), ages 15 to 39, are diagnosed with cancer,1 and they are immediately faced with myriad challenges and disruptions in their life stages, including psychosocial distress; interruptions in their education, career, and...
Long-Term Health Risks for Testicular Cancer Survivors Differ by Chemotherapy Regimen
Long-term effects on renal function, cardiovascular risk, and overall health burden in survivors of testicular cancer differed according to the chemotherapy regimen each patient received, according to the results of a large real-world study published in JNCCN—Journal of the National Comprehensive...
FDA Approves Encorafenib for Metastatic BRAF V600E–Mutated Colorectal Cancer
On February 24, the U.S. Food and Drug Administration (FDA) granted traditional approval to the kinase inhibitor encorafenib (Braftovi) in combination with cetuximab and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, ...
I Used AI to Supplement My Oncology Care—It Reshaped My Treatment Plan
A year ago, I was confronting a series of symptoms—including rapid weight loss, abdominal distress, fatigue, and heart issues—that I couldn’t explain. I was just 60 years old and had been in good health, but now I sensed that something was seriously wrong. I made appointments with my primary care...
Leader in Global Cancer Care, Paul E. Goss, MD, PhD, FRCPC, FRCP Dies at 70
The oncology community is mourning the loss of Paul E. Goss, MD, PhD, FRCPC, FRCP, who died on December 19, 2025, at his home in Hopkinton, Massachusetts, from multiple system atrophy—a rare, progressive neurologic disorder with symptoms resembling those of Parkinson’s disease. He was 70 years ...
Introducing ASCO AI in Oncology
In February, ASCO and Conexiant launched ASCO AI in Oncology (ascoai.org), a digital platform dedicated to understanding how artificial intelligence (AI) is impacting cancer care. “Our goal with this hub is to empower oncology professionals with knowledge and the tools to adapt to a rapidly...
ASCO’s First Living Guideline in GU Cancers Reflects Recent Practice-Changing Trials on Systemic Treatment of mCRPC
ASCO has published an updated guideline on systemic therapy for patients with metastatic castration-resistant prostate cancer (mCRPC), representing ASCO’s first Living Guideline in the area of prostate cancer and the first in any genitourinary (GU) cancer.1 “Guidelines will become less useful if...
AI-Selected Biomarker Guides First-Line Treatment Selection in Advanced Pancreatic Cancer
A computational histology–based artificial intelligence (AI) platform was able to identify a biomarker that could predict treatment benefit between two chemotherapy options for patients with advanced pancreatic cancer, according to the results of a study presented in a poster at the 2026 ASCO...
Microplastics Found in 90% of Prostate Cancer Samples
Microplastics and nanoplastics were identified in samples from 9 out of 10 patients with prostate cancer, with greater levels of these small plastic fragments inside tumors than in nearby normal tissue, according to findings from a small pilot study that will be presented at the upcoming 2026 ASCO...
Proximity to Nuclear Power Plants and Cancer Risk
U.S. counties located closer to operational nuclear power plants (NPPs) have higher rates of cancer mortality than those located farther away, according to a new study published by Alwadi et al in Nature Communications. The study is the first of the 21st century to analyze proximity to NPPs and...
Can a New Testing Method Allow More Patients With Bladder Cancer to Avoid Radical Cystectomy?
Researchers have reported findings that may help redefine treatment for patients with muscle-invasive bladder cancer, a potentially aggressive form of the disease that is traditionally treated with surgical removal of the bladder. The study, published by Matthew D. Galsky, MD, and colleagues in the ...
New Biomarker May Predict Chemotherapy Response in Patients With Triple-Negative Breast Cancer
Researchers have developed a new computational approach designed to better account for changes in gene expression within tumors relative to their unique microenvironments. This approach outperformed current methods for predicting chemotherapy response in patients with triple-negative breast ...
First Results of Phase III OLYMPIA-3: Odronextamab Plus CHOP in Untreated DLBCL
The bispecific antibody odronextamab plus standard CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) chemotherapy yielded robust and durable responses in treatment-naive patients with diffuse large B-cell lymphoma (DLBCL), based on the first results of the phase III OLYMPIA-3 study...
Acral Melanoma: Ancestry and Genetics Impact Outcomes
A genetic study of Mexican patients with acral melanoma revealed that the cancer subtype encompasses three groups that may each have distinct gene expressions associated with different survival outcomes, according to findings published in Nature. “We found that acral melanoma is not a single...
CLL/SLL: FDA Approves Combination of Acalabrutinib and Venetoclax
On February 19, the U.S. Food and Drug Administration (FDA) approved the Bruton’s tyrosine kinase inhibitor acalabrutinib (Calquence) tablets and capsules in combination with the BCL2 inhibitor venetoclax (Venclexta) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma...
AI Tool Classifies Pediatric Brain Tumors via Liquid Biopsy
Researchers developed a deep neural network, M-PACT, to identify and classify brain tumors in pediatric patients from the subnanogram-input cell-free DNA of methylomes, according to findings published in Nature Cancer. “This is a next-generation assay and computational framework that we’ve...
High Response Rates With Front-Line Pivekimab Sunirine in BPDCN
Treatment with the novel CD123-targeting antibody-drug conjugate pivekimab sunirine led to a high rate of complete and durable responses in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), especially among patients being treated in the front-line setting. The antibody-drug...
Multidisciplinary Radiopharmaceutical Therapy Symposium: Highlights From the Inaugural New Meeting From ASTRO
New research highlighting the growing potential of radiopharmaceutical therapies (RPT) to improve outcomes for people with cancer was presented at the inaugural Multidisciplinary Radiopharmaceutical Therapy Symposium, which took place in Palm Desert, California, and online on February 17 and 18....
Genetics Pioneer Zsofia K. Stadler, MD, to Lead JCO Precision Oncology
Zsofia K. Stadler, MD, has been appointed as the next Editor-in-Chief of JCO Precision Oncology (JCO PO), an ASCO journal. JCO PO is a peer-reviewed, online-only journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and...
Adding Encorafenib and Cetuximab to FOLFIRI Shows Benefit in BRAF-Mutant Colorectal Cancer
The addition of the BRAF inhibitor encorafenib and the EGFR antibody cetuximab to chemotherapy with FOLFIRI (leucovorin, fluorouracil, and irinotecan) in the first-line treatment of BRAF V600E–mutated metastatic colorectal cancer led to a significant improvement in overall response rate—compared...
Topline Progression-Free Survival Results From BREAKWATER in Metastatic Colorectal Cancer Newly Announced
Pfizer has announced positive topline progression-free survival results from cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating encorafenib in combination with cetuximab and FOLFIRI (fluorouracil, leucovorin, and irinotecan) in patients with previously untreated...
Cancer Surgery Outcomes Similar Between Rural and Urban Facilities
Patients in rural areas who received surgery locally for their lung or colon cancer had comparable surgical outcomes and mortality rates to patients who underwent surgery in an urban facility, according to the results of an analysis published in the Journal of the American College of Surgeons....
COMMIT: First-Line Atezolizumab Plus FOLFOX and Bevacizumab Regimen in Metastatic Colorectal Cancer
In the phase III COMMIT trial, a regimen combining atezolizumab plus bevacizumab and standard chemotherapy significantly improved progression-free survival and response rates over atezolizumab monotherapy in patients with previously untreated mismatch repair deficient (dMMR) or microsatellite...
FDA Approves Once-Monthly Dosing Schedule for Amivantamab and Hyaluronidase-lpuj
Today, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved a new, simplified monthly dosing schedule for amivantamab and hyaluronidase-lpuj (Rybrevant Faspro). When administered in combination with oral lazertinib for the first-line treatment EGFR-mutated...
ASH Guidelines on Management of Newly Diagnosed and Relapsed/Refractory ALL in AYA Patients
The American Society of Hematology (ASH) released guidelines on front-line management of acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs), as well as the management of relapsed or refractory disease in this population. Both guidelines, grounded in evidence-based practice,...
Nonmetastatic Breast Cancer: Treatment Strategies After Denosumab Discontinuation in Patients Treated With Aromatase Inhibitors
Aromatase inhibitors are a cornerstone of adjuvant therapy for hormone receptor–positive breast cancer, significantly reducing recurrence and mortality. However, by suppressing estrogen production, aromatase inhibitors can accelerate bone loss and increase fracture risk. To counter this,...
Oncolytic Virus Triggers Immune System Against Glioblastoma Cells
Treatment with a single injection of an oncolytic virus induces persistent T cell–mediated immunity in glioblastoma, according to findings from a trial published in Cell. “Patients with glioblastoma have not benefited from immunotherapies that have transformed patient care in other cancer types...
FDA Approves Labeling Changes to Menopausal Hormone Therapy Products
The U.S. Food and Drug Administration (FDA) has approved drug labeling changes to six menopausal hormone therapy products, also known as hormone replacement therapy (HRT), to clarify risk considerations for these drugs. Specifically, risk statements related to cardiovascular disease, breast cancer, ...
ASH Publishes Clinical Guidelines on AL Amyloidosis Diagnosis
The American Society of Hematology (ASH) has released clinical practice guidelines on the diagnosis of light chain (AL) amyloidosis, which were published in Blood Advances. Additionally, the expert panel behind the guidelines also published a scoping review about the clinical features of systemic...
FDA Approves TTFields Device for Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) has approved a first-of-its-kind device for the treatment of adult patients with locally advanced pancreatic cancer. Optune Pax, developed by Novocure, is a portable, noninvasive device that delivers alternating electrical fields, known as tumor treating...
COA Survey Shows Insurer Utilization Management Interferes With Cancer Treatment Decisions
A national survey of independent community oncology practices has found that utilization management tactics imposed by health insurers and pharmacy benefit managers (PBMs) delay cancer treatment, interfere with physician-directed care, and increase administrative and financial burdens on practices...
Rural Populations Face Greater Barriers as Nonmedical Costs Hinder Cancer Clinical Trial Access
Earlier this week, 25 health-care organizations proposed that the Health and Human Services Office of Inspector General adopt a new regulatory safe harbor from the Anti-Kickback Statute that would allow clinical trial sponsors to financially support patients to offset indirect or nonmedical costs...
PSMA PET/CT-Guided Radiotherapy After Prostatectomy
New research published by Nikitas et al in JNCCN—Journal of the National Comprehensive Cancer Network found that incorporating information from prostate-specific membrane antigen (PSMA) positron-emission tomography/computed tomography (PET/CT) scans may be able to predict progression-free survival...
FDA Approves Pembrolizumab With Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
On February 10, the U.S. Food and Drug Administration (FDA) approved the PD-1 inhibitor pembrolizumab (Keytruda) as well as pembrolizumab and the recombinant human enzyme,berahyaluronidase alfa-pmph (Keytruda Qlex) in combination with paclitaxel, with or without bevacizumab. [Pembrolizumab plus...
Early Findings From First Human Study of In Vivo CAR T in Myeloma
The first-in-human clinical trial of an in vivo CAR T-cell therapy for multiple myeloma has shown encouraging clinical outcomes at an early time point, with a safety profile and ease of administration that indicates the off-the-shelf KLN-1010 could be easily deployable, researchers from Australia...
ASH 2025: Myelofibrosis Roundup
For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being paired with the commonly used JAK inhibitor ruxolitinib, as reflected by a wealth of studies...
Early Results Demonstrate Safety and Efficacy of Mutant Calreticulin–Specific Monoclonal Antibody in Myelofibrosis
In patients with CALR exon 9–mutated myelofibrosis who were resistant or intolerant to prior Janus kinase (JAK) inhibitor therapy or ineligible for such treatment, the first-in-class mutant calreticulin–specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib...
Epcoritamab Plus R2 in Follicular Lymphoma: A Potential New Treatment Standard
In patients with follicular lymphoma who received at least one prior line of therapy, the combination of the bispecific antibody epcoritamab-bysp and rituximab–lenalidomide (R2) reduced the risk of disease progression or death by almost 80% over R2 alone, based on the primary analysis of the phase...
GIMEMA ALL2820: Chemotherapy-Free Regimen Studied in Front-Line Setting
As front-line therapy, a chemotherapy-free regimen combining the tyrosine kinase inhibitor (TKI) ponatinib and the bispecific T-cell engager blinatumomab significantly outperformed standard treatment with imatinib plus chemotherapy in adults with newly diagnosed Philadelphia chromosome–positive...
ASCO and Conexiant Launch ASCO AI in Oncology
The American Society of Clinical Oncology (ASCO®) and Conexiant today announced the launch of ASCO AI in Oncology, a premier digital destination designed to help oncology professionals navigate the transformative role of artificial intelligence (AI) in cancer care. Launching this initiative marks...
A New Risk Model for Esophagectomy Draws on the STS National Database
A nationwide, real-world analysis using the Society of Thoracic Surgeons (STS) General Thoracic Surgery Database (GTSD) from 2012 to 2023 evaluated over 16,000 adults who underwent esophagectomy for primary esophageal cancer to develop and validate a long-term all-cause mortality risk model. The...
